SCHEMBL2675708

SCHEMBL2675708

CC([C]=O)c1ccccc1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.38
ALOX15 P16050 2/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 2/20 0.34
ALDH1A1 P00352 5/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
FAAH O00519 1/20 0.33
MGLL Q99685 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ADORA2A P29274 2/20 0.32
PTPRC P08575 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB2 P47870 1/20 0.32
ADRA2B P18089 1/20 0.32
PTGS1 P23219 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1888537 0.78 CYP3A4 (0.38) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
Hydrochloric Acid SCHEMBL27897741 0.77 CYP3A4 (0.38) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL910441 0.76 ESR1 (0.46) ALDH1A1GABRA1GABRB2ADRA2BGAA
SCHEMBL9165861 0.76 ESR1 (0.46) ALDH1A1GABRA1GABRB2ADRA2BGAA
SCHEMBL11503347 0.75 CYP3A4 (0.35) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL9818280 0.74 HTT (0.42) CYP3A4ALOX15ALDH1A1CA1CA2
SCHEMBL911040 0.74 GABRA1 (0.58) CYP3A4ALOX15SMN1; SMN2TDP1ALDH1A1
SCHEMBL6141021 0.74 CYP3A4 (0.40) CYP3A4ALDH1A1GAACYP2C9
SCHEMBL6141168 0.74 ADRB2 (0.42) CYP3A4TDP1ALDH1A1L3MBTL1KDM4E
SCHEMBL16512108 0.74 CYP3A4 (0.48) CYP3A4ALOX15CASP1CASP7SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173128-B2 Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody IRM LLC (BM) 2012-05-08 US disclosed
EP-1576179-B1 METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS IRM LLC (BM) 2010-09-15 EP disclosed
WO-2008154439-A1 METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS IRM LLC (BM) 2008-12-18 WO disclosed
WO-2008066854-A2 METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS NOVARTIS AG (CH) 2008-06-05 WO disclosed
US-7229617-B2 Methods and compositions for inducing apoptosis in cancer cells IRM LLC (BM) 2007-06-12 US disclosed
US-20070128204-A1 Methods and compositions for inducing apoptosis in cancer cells IRM LLC (BM) 2007-06-07 US disclosed
EP-1576179-A4 METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS IRM LLC (BM) 2007-06-06 EP disclosed
EP-1656390-A2 COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF MIGENIX INC. (CA) 2006-05-17 EP disclosed
EP-1576179-A2 METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS IRM LLC (BM) 2005-09-21 EP disclosed
US-20050079172-A1 Methods and compositions for inducing apoptosis in cancer cells IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2005-04-14 US disclosed
WO-2004050895-A2 METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS IRM LLC (BM) 2004-06-17 WO disclosed
US-20040005562-A9 Comprises tranferase protein associated with biosynthesis of taxoids for treating breast and ovarian cancers WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION 2004-01-08 US disclosed
US-20030108891-A1 Transacylases of the paclitaxel biosynthetic pathway WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION 2003-06-12 US disclosed
EP-1178784-A1 NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS Pfizer Products Inc. (US) 2002-02-13 EP disclosed
EP-1173413-A1 USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS Novartis AG (CH) 2002-01-23 EP disclosed
WO-2000071107-A2 NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS PFIZER PRODUCTS INC. (US) 2000-11-30 WO disclosed
WO-2000064863-A1 USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS NOVARTIS AG (CH) 2000-11-02 WO disclosed
US-4310551-A Pharmacologically active substituted 1,2,4-triazines DIAMOND SHAMROCK CORPORATION (US) 1982-01-12 US disclosed
US-4251527-A ANTIINFLAMMATORY AGENTS DIAMOND SHAMROCK CORPORATION (US) 1981-02-17 US disclosed
US-4157392-A HYPOTENSIVE AGENTS, ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS AND NERVOUS SYSTEM EFFECTS DIAMOND SHAMROCK CORPORATION (US) 1979-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050079172-A1 Methods and compositions for inducing apoptosis in cancer cells BAD, BAX, CASP3 CYP3A4 3056/4885ALOX15 476/4885CASP1 66/4885
US-20070128204-A1 Methods and compositions for inducing apoptosis in cancer cells BAD, BAX, BID CYP3A4 4496/4885ALOX15 766/4885CASP1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.